QC
SAGE

Quadrature Capital’s Sage Therapeutics SAGE Stock Holding History

Quadrature Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-84,964
Closed -$675K – 1427
2025
Q1 		$675K Buy
+84,964
New +$622K 0.02% 511

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Quadrature Capital's SAGE Position: Q2 2025 in Review

Quadrature Capital sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 84,964 shares — an estimated $675K sold.

Quadrature Capital first reported a position in SAGE in Q1 2025 and held it in 1 quarter. The position peaked at $675K in Q1 2025. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Quadrature Capital reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quadrature Capital sold 84,964 Sage Therapeutics shares in Q2 2025, an estimated $675K.
  • Quadrature Capital first reported a position in Sage Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quadrature Capital's Sage Therapeutics position peaked at $675K in Q1 2025.
  • 191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Quadrature Capital's 13F filing for Q2 2025, filed 13 Aug 2025.